Conference Correspondent
PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy. Read More ›
A leading cancer clinic has developed an innovative response-adapted treatment protocol for newly diagnosed patients with multiple myeloma. Read More ›
Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug. Read More ›
Daratumumab in combination with lenalidomide plus dexamethasone specifically induces robust increases in T-cell clonality. The finding provides support for an immune modulatory mechanism of daratumumab. Read More ›
Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand. Read More ›
Compared with standard-of-care therapies delivered in a real-world setting, daratumumab monotherapy extends overall survival in patients with heavily pretreated and highly refractory multiple myeloma. Read More ›
Ali McBride speaks about three new target therapies that have recently come to market. Read More ›
Ali McBride provides some ideas to promoting oral adherence. Read More ›
R. Donald Harvey offers suggestions for what might help with greater medication adherence. Read More ›
Ali McBride offers suggestions and ways to help patients with out-of-pocket expenses. Read More ›